Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Special Issue: Recent Advances in Microglia Research.

International journal of molecular sciences·2025
Same author

Astrocytes phenomics as new druggable targets in healthy aging and Alzheimer's disease progression.

Frontiers in cellular neuroscience·2025
Same author

Prolonged incubation with Δ<sup>9</sup>-tetrahydrocannabinol but not with cannabidiol induces synaptic alterations and mitochondrial impairment in immature and mature rat organotypic hippocampal slices.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model.

Frontiers in pharmacology·2024
Same author

Editorial: The role of the microbiota-gut-brain axis in the pathogenesis of neurodegenerative diseases.

Frontiers in neuroscience·2024
Same author

Morphofunctional Investigation in a Transgenic Mouse Model of Alzheimer's Disease: Non-Reactive Astrocytes Are Involved in Aβ Load and Reactive Astrocytes in Plaque Build-Up.

Cells·2023

Related Experiment Video

Updated: Jun 18, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Cholinesterase inhibitors and memory.

Giancarlo Pepeu1, Maria Grazia Giovannini

  • 1Department of Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy. giancarlo.pepeu@unifi.it

Chemico-Biological Interactions
|November 28, 2009
PubMed
Summary
This summary is machine-generated.

Cholinesterase inhibitors (ChEIs) help mild to moderate Alzheimer's Disease (AD) by boosting acetylcholine. However, their effects on memory consolidation and retrieval in AD patients are limited, with potential impairment at higher levels.

More Related Videos

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice
08:52

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice

Published on: August 30, 2017

Preparation of Oligomeric &beta;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Related Experiment Videos

Last Updated: Jun 18, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice
08:52

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice

Published on: August 30, 2017

Preparation of Oligomeric &beta;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Cholinesterase inhibitors (ChEIs) are a consensus treatment for mild to moderate Alzheimer's Disease (AD).
  • A significant number of patients do not respond to ChEIs, and therapeutic effects are often short-lived.
  • ChEIs function by inhibiting cholinesterase (ChE) and increasing brain acetylcholine (ACh) levels, impacting cognitive processes.

Purpose of the Study:

  • To review cognitive processes influenced by ChEI treatment, focusing on those dependent on cholinergic pathways.
  • To explore the role of the cholinergic system in cognition through animal models and human studies.
  • To evaluate the specific effects of ChEIs on memory consolidation and retrieval in Alzheimer's Disease.

Main Methods:

  • Review of microdialysis experiments in animals to assess cholinergic system involvement in various cognitive functions.
  • Analysis of studies on healthy human subjects investigating the impact of cholinergic system stimulation on cognition.
  • Examination of rating scale data from AD patients treated with ChEIs to identify specific areas of improvement.

Main Results:

  • Animal studies indicate cholinergic involvement in attention, working memory, spatial memory, explicit memory, and information encoding.
  • Human studies confirm that cholinergic stimulation enhances attention, stimulus detection, perceptual processing, and information encoding.
  • In AD patients, ChEIs show improvements in attention, executive functions, communication, expressive language, and mood stability, but may impair memory consolidation and retrieval.

Conclusions:

  • The efficacy of ChEIs in AD is limited, particularly concerning memory processes, due to cholinergic system degeneration and diffuse synaptic loss.
  • While ChEIs improve certain cognitive domains like attention and executive function, their impact on memory consolidation and retrieval may be negative at higher ACh levels.
  • Understanding the specific cognitive domains affected by ChEIs is crucial for managing Alzheimer's Disease treatment expectations.